UCB (OTCMKTS:UCBJF) Sets New 52-Week High – What’s Next?

Shares of UCB SA (OTCMKTS:UCBJF) hit a new 52-week high during trading on Wednesday . The company traded as high as $345.39 and last traded at $341.1250, with a volume of 232 shares trading hands. The stock had previously closed at $335.24.

Analysts Set New Price Targets

UCBJF has been the subject of several recent research reports. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a report on Monday. Barclays reiterated an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a report on Monday, December 8th. Finally, Stephens restated an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, UCB currently has a consensus rating of “Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The company has a 50 day moving average price of $302.06 and a 200 day moving average price of $275.90.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.